title: Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.
abstract: OBJECTIVE
  To evaluate posterior and anterior segment safety of an intracameral injection of moxifloxacin 0.5% ophthalmic solution as prophylaxis for endophthalmitis in patients having cataract surgery.
  
  
  METHODS
  Three private practices, the University of Minnesota School of Medicine, Stillwater, Minnesota, and the University of Cincinnati, Cincinnati, Ohio, USA.
  
  
  METHODS
  In this prospective randomized combined-center open-label trial, 57 eyes of 47 patients were treated with intracameral moxifloxacin (250 mug/0.050 mL) or an equal volume of balanced salt solution at the conclusion of cataract surgery with intraocular lens implantation. Safety parameters, including visual acuity, intraocular pressure, endothelial cell counts, corneal pachymetry, corneal clarity and edema, and anterior chamber cells and flare, were evaluated preoperatively and for 3 months postoperatively.
  
  
  RESULTS
  Optical coherence tomography results showed no statistically significant differences between the 2 treatment groups preoperatively or at 3 months. There were also no statistically significant differences between the 2 treatment groups in all other parameters preoperatively or at 1 day, 2 to 4 weeks, or 3 months. No study-related adverse events occurred.
  
  
  CONCLUSIONS
  There was no increased safety risk associated with a 250 mug/0.050 mL intracameral injection of moxifloxacin, which appears to be safe in the prophylaxis of endophthalmitis after cataract surgery.
authors: Associated Eye Care, 232 Main Street, Stillwater, MN 55082, USA. sslane@associatedeyecare.com
authors: Stephen S
authors: SS
authors: Lane
authors: Robert H
authors: RH
authors: Osher
authors: Samuel
authors: S
authors: Masket
authors: Shaleen
authors: S
authors: Belani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000867:Anterior Chamber / Q000187:drug effects*; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D001372:Aza Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D002452:Cell Count; D009877:Endophthalmitis / Q000382:microbiology / Q000517:prevention & control*; D004728:Endothelium, Corneal / Q000473:pathology; D015818:Eye Infections, Bacterial / Q000382:microbiology / Q000517:prevention & control; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D007429:Intraocular Pressure; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000627:therapeutic use; D018918:Phacoemulsification; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D009883:Ophthalmic Solutions; D011804:Quinolines; D000077266:Moxifloxacin